Novo Nordisk A/S (NYSE:NVO) Shares Sold by Procyon Advisors LLC

Procyon Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 12.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,471 shares of the company’s stock after selling 8,178 shares during the period. Procyon Advisors LLC’s holdings in Novo Nordisk A/S were worth $4,772,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. Natixis Advisors LLC boosted its holdings in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC lifted its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Talbot Financial LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $4,066,000. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $86,000. Finally, Zions Bancorporation N.A. grew its stake in Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after acquiring an additional 6,726 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on NVO. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Trading Up 0.4 %

Shares of NVO stock opened at $83.26 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $80.05 and a twelve month high of $148.15. The company has a market capitalization of $373.61 billion, a P/E ratio of 26.94, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The business’s 50 day moving average is $98.82 and its two-hundred day moving average is $117.93.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.